Respiratory syncytial virus (RSV) is an important cause of disease in older adults.
Safety and immunogenicity of a stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate with/without adjuvant in adults 65 - 85 years.
<h3>What are the results of Study of a Respiratory Syncytial Virus ?</h3>
All RSVpreF vaccine candidates elicited robust and persistent serum neutralizing responses when administered alone or with SIIV.
There was no notable difference in neutralizing response between the formulations, including those containing CpG. In the Month 0,2 Cohort, there was no booster effect of dose 2.
SIIV responses were similar or slightly lower with concomitant administration of RSVpreF. Most systemic and local reactions were mild and more frequent after RSVpreF than placebo.
Learn more about Respiratory Syncytial Virus here:
